🇺🇸 FDA
Pipeline program

Atomoxetine hydrochloride

NIDA-16264-1

Approved small_molecule completed

Quick answer

Atomoxetine hydrochloride for Attention Deficit Disorder With Hyperactivity is a Approved program (small_molecule) at BRIGHT MINDS BIOSCIENCES INC. with 1 ClinicalTrials.gov record(s).

Program details

Company
BRIGHT MINDS BIOSCIENCES INC.
Indication
Attention Deficit Disorder With Hyperactivity
Phase
Approved
Modality
small_molecule
Status
completed

Clinical trials